Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Files An 8-K Regulation FD Disclosure
Item 7.01Regulation FD Disclosure.
On April 4, 2019, management of Aclaris Therapeutics, Inc. (the “Company”) will host investor meetings during the William Blair & Company 3rd Annual Late-Stage Therapeutics Conference in New York, New York. The investor meetings will include a slide presentation. A copy of this slide presentation is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
In accordance with General Instruction B.2. of Form 8-K, the information in this Item 7.01 and Exhibit 99.1 hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any of the Company’s filings under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any incorporation language in such a filing, except as expressly set forth by specific reference in such a filing.
Item 9.01 Financial Statements and Exhibits.
Aclaris Therapeutics, Inc. Exhibit
EX-99.1 2 ex-99d1.htm EX-99.1 Exhibit 99.1© Copyright 2019 Aclaris Therapeutics,…
To view the full exhibit click
About Aclaris Therapeutics, Inc. (NASDAQ:ACRS)
Aclaris Therapeutics, Inc. is a United States-based clinical-stage specialty pharmaceutical company. The Company is focused on identifying, developing and commercializing drugs to address the needs in dermatology. Its lead drug candidate, A-101 Topical Solution, is a hydrogen peroxide topical solution that the Company is developing as a prescription treatment for seborrheic keratosis (SK). It has completed approximately three Phase II clinical trials of A-101. It has initiated over two multi-center, double blind Phase III clinical trials and an open label Phase III clinical trial of A-101 in patients with SK. It also intends to develop A-101 as a prescription treatment for common warts, also known as verruca vulgaris, and A-102, a gel dosage form of hydrogen peroxide, as a prescription treatment for SK and common warts. It has initiated a Phase II clinical trial to evaluate A-101 for the treatment of common warts.